Guidelines for Using Diclofenac (NSAID)
Diclofenac should be used with caution and only when safer alternatives are insufficient, particularly in patients with cardiovascular disease, as it is associated with a significantly increased risk of mortality (HR 2.40) compared to other NSAIDs. 1
General Recommendations for Diclofenac Use
Indications
- FDA-approved for treatment of primary dysmenorrhea, mild to moderate pain, and relief of signs and symptoms of osteoarthritis and rheumatoid arthritis 2
- Should be used at the lowest effective dose for the shortest possible duration 2
Contraindications
- Known hypersensitivity to diclofenac or components of the drug product 2
- History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs 2
- In the setting of coronary artery bypass graft (CABG) surgery 2
- Use with extreme caution in patients with established cardiovascular disease 1
Stepped-Care Approach to Pain Management
First-Line Options (Before Considering Diclofenac)
- Begin with acetaminophen, small doses of narcotics, or nonacetylated salicylates 1
- Non-pharmacological approaches should be considered as first-line treatment 1
Second-Line Options
- If first-line therapy is insufficient, consider nonselective NSAIDs with lower cardiovascular risk profiles, such as naproxen 1
Third-Line Options
- Diclofenac and other NSAIDs with higher degrees of COX-2 selectivity should only be considered when intolerable discomfort persists despite attempts with first and second-line options 1
- When used, administer at the lowest effective dose for the shortest possible time 1
Special Considerations
Cardiovascular Risk
- Diclofenac has been associated with significantly increased cardiovascular risk (HR 2.40) compared to other NSAIDs 1
- Risk appears to be dose-related and amplified in patients with established cardiovascular disease 1
- In patients with history of myocardial infarction, diclofenac was associated with higher risk of death (HR 2.40) compared to ibuprofen (HR 1.50) 1
Gastrointestinal Risk
- Consider adding a proton pump inhibitor in patients at increased risk of GI complications 3
- Fixed combination of diclofenac with misoprostol may be considered for patients at high risk for NSAID-related gastrointestinal complications 3
Pregnancy and Fertility
- For early pregnancy exposure, data show no evidence of increased risk of miscarriage or teratogenicity 1
- Should be restricted to first and second trimester and discontinued after gestational week 28 1
- May interfere with ovulation; women with difficulty conceiving should consider discontinuing NSAIDs 1
- When needed during pregnancy, prefer nonselective NSAIDs with short half-life (e.g., ibuprofen) at lowest effective dose for short duration (7-10 days) 1
Drug Interactions
- Monitor patients taking diuretics for signs of worsening renal function 2
- May increase serum concentration and prolong half-life of digoxin 2
- Can increase plasma lithium levels and reduce renal lithium clearance 2
- May increase risk for methotrexate toxicity 2
- May increase cyclosporine's nephrotoxicity 2
- Avoid concomitant use with other NSAIDs or salicylates 2
Topical Formulations
- Topical diclofenac is preferred over systemic treatment due to favorable safety profile 1
- Topical diclofenac gel has shown improvements in pain and function with similar low rates of adverse effects in both low and high-risk patients 1
Monitoring and Follow-up
- Monitor for gastrointestinal bleeding, ulceration, and perforation 2
- Watch for signs of cardiovascular events, particularly in patients with pre-existing cardiovascular disease 1
- Monitor renal function, especially in patients taking diuretics or with pre-existing renal impairment 2
Common Pitfalls to Avoid
- Avoid using ibuprofen in patients on aspirin therapy, as it blocks the antiplatelet effects of aspirin 1
- Do not use diclofenac as first-line therapy when safer alternatives may provide adequate pain relief 1
- Avoid long-term use, particularly in elderly patients and those with cardiovascular risk factors 1
- Do not continue NSAIDs during hospitalization for acute coronary events 1